Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors.

Immunity - 14 Jul 2026

Borden Elizabeth S, Castellano David, Kantzos Emily A, Hughes Alysia, Leibovit-Reiben Zachary, Stockard Alyssa, Choudhary Anirudh, Ma Tao, Li Xing, Mangold Aaron R, Gutenkunst Ryan N, LaFleur Bonnie J, Buetow Kenneth H, Wilson Melissa A, Hastings Karen Taraszka

Abstract excerpt

T cell targeting of cancer cells alters the tumor antigen landscape in preclinical models. Here, we examined the impact of immunoediting on the antigenic landscape of primary, treatment-naive human tumors. Cutaneous squamous cell carcinoma tumors from immunocompetent and immunosuppressed patients revealed consistent tumor mutational signatures; however, high-immune-infiltrate tumors from immunocompetent patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocompatibility Antigens Class I

Share to Immunocompromised Host

Share to Mutation

Share to Skin Neoplasms

Share to T-Lymphocytes

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 42276071
DOI: 10.1016/j.immuni.2026.05.005
PMCID: PMC13428410

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors.PMID 42276071Read ↗

Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.Semantic proximity Read ↗

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read ↗

Integrated modeling to implicate evolving neoantigen-T cell interplays and immunotherapy efficacy in tumorsSemantic proximity Read ↗

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Semantic proximity Read ↗

Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancersSemantic proximity Read ↗

Distinct sets of molecular characteristics define tumor-rejecting neoantigensSemantic proximity Read ↗

Immunological-based approaches for cancer therapy.Semantic proximity Read ↗

A novel integrated approach to predicting cancer immunotherapy efficacySemantic proximity Read ↗

Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.Semantic proximity Read ↗

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaSemantic proximity Read ↗

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Semantic proximity Read ↗

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.